Summary: Those with hepatitis C often suffer from fatigue. This study looked at aspects of fatigue from a cognitive-behavioural perspective, in 14 people with hep C and diagnosed clinical fatigue. The results showed that there are unique aspects of fatigue related to hep C and that additional knowledge and research, using a cognitive-behavioural framework, may be beneficial for those with hep C fatigue.
Summary: Limiting populations eligible for clinical trials for direct antiviral agents (DAAs) may have resulted in a need now for additional real world data for hep C DAA treatments.
Summary: The researchers analyzed published studies and found that those with hep C had an increased risk of cardiovascular disease.
- Simeprevir Plus Sofosbuvir (12 and 8 Weeks) in HCV Genotype 1-Infected Patients Without Cirrhosis: OPTIMIST-1, a Phase 3, Randomized Study by Paul Kwo, et al.
Summary: Galexos (simeprevir) + Sovaldi (sofosbuvir) for 12 weeks is effective when treating those with hep C genotype 1, non-cirrhotic patients, including those with Q80K (97% with 12 weeks of treatment; 83% with 8 weeks).
Summary: There isn’t a hep C treatment that is highly successful for those with advanced cirrhosis or those who redeveloped hep C after a liver transplant. This study found that the combination treatment daclatasvir, sofosbuvir, and ribavirin was safe and well tolerated when take by patients with hep C genotype 1 (76%), 2, 3, 4, or 6 with hep C recurrence after a liver transplant or with advanced cirrhosis.
Summary: The combination treatment daclatasvir, sofosbuvir, and ribavirin was safe and well tolerated when take for 12 or 16 weeks by patients with hep C genotype 3 with advanced liver disease.
Summary: This study compared hep C patients with advanced liver disease (decompensated liver cirrhosis) treated with direct antiviral agents (DAAs) to untreated patients with advanced liver disease. Those treated were cured and experienced liver function improvement.
Summary: The study followed patients who had been infected through injecting drug use (IDU) and were successfully cured from hep C. The study found that reinfection was common in those who went back to IDU.
Summary: The study’s aim was to determine the prevalence of cirrhosis among American adults with hep C, including those unaware of their infection. The study showed that those who didn’t know of their hep C infection were just as likely to have liver cirrhosis as those who knew of their infection.
- Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study by Armand Abergel, et al.
Summary: The study assessed the efficacy and safety of the combination of ledipasvir and sofosbuvir on patients with hep C genotype 5 who had and hadn’t already tried treatment. Conclusion: the treatment is effective and well-tolerated. Everyone completed the 12 weeks of treatment successfully and 39/41 were cured.
* Time period was between January 1st and February 5th, 2016.